Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.
Open Access
- 1 February 1995
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 95 (2) , 774-782
- https://doi.org/10.1172/jci117726
Abstract
Mildly oxidized low density lipoprotein (MM-LDL) produced by oxidative enzymes or cocultures of human artery wall cells induces endothelial cells to produce monocyte chemotactic protein-1 and to bind monocytes. HDL prevents the formation of MM-LDL by cocultures of artery wall cells. Using albumin treatment and HPLC we have isolated and partially characterized bioactive oxidized phospholipids in MM-LDL. Platelet activating factor-acetylhydrolase (PAF-AH), a serine esterase, hydrolyzes short chain acyl groups esterified to the sn-2 position of phospholipids such as PAF and particular oxidatively fragmented phospholipids. Treatment of MM-LDL with PAF-AH (2-4 x 10(-2) U/ml) eliminated the ability of MM-LDL to induce endothelial cells to bind monocytes. When HDL protected against the formation of MM-LDL by cocultures, lysophosphatidylcholine was detected in HDL; whereas when HDL was pretreated with diisopropyl fluorophosphate, HDL was no longer protective and lysophosphatidylcholine was undetectable. HPLC analysis also revealed that the active oxidized phospholipid species in MM-LDL had been destroyed after PAF-AH treatment. In addition, treatment of MM-LDL with albumin removed polar phospholipids that, when reisolated, induced monocyte binding to endothelial cells. These polar phospholipids, when treated with PAF-AH, lost biological activity and were no longer detected by HPLC. These results suggest that PAF-AH in HDL protects against the production and activity of MM-LDL by facilitating hydrolysis of active oxidized phospholipids to lysolipids, thereby destroying the biologically active lipids in MM-LDL.Keywords
This publication has 46 references indexed in Scilit:
- Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1986
- Rapid separation of lipid classes in high yield and purity using bonded phase columns.Journal of Lipid Research, 1985
- Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1984
- LIPOPROTEIN METABOLISM IN THE MACROPHAGE: Implications for Cholesterol Deposition in AtherosclerosisAnnual Review of Biochemistry, 1983
- Enhanced macrophage degradation of biologically modified low density lipoprotein.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1983
- Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophagesProceedings of the National Academy of Sciences, 1980
- Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).Journal of Biological Chemistry, 1979
- Altered Metabolism (In Vivo and In Vitro) of Plasma Lipoproteins after Selective Chemical Modification of Lysine Residues of the ApoproteinsJournal of Clinical Investigation, 1979
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959